This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SITC 2020
Presentations

Brentuximab vedotin| Research | Abstract 696
Brentuximab vedotin, a CD30 targeting antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo

Tisotumab vedotin | Research | Abstract 617
Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death

Ladiraztumab vedotin | Breast Cancer | Abstract 323
Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients

SEA-CD40 | Research | Abstract 438
Synergy between SEA-CD40 and chemotherapeutics drives curative anti-tumor activity in pre-clinical models

SEA-TGT | Research | Abstract 250
SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon FcγR engagement

Research | Research | Abstract 618
Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications
Videos
Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death
Tisotumab vedotin | Research | Abstract 617